ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS) Files An 8-K Other Events
Item 8.01 Other Events.
On May 28, 2018, Oncosec Medical Incorporated (“Oncosec” or the “Company”) announced the closing of its previously announced underwritten public offering. With the closing of this transaction, the Company also announced that its current pro forma unaudited cash, cash equivalents and investment balance exceeds $30 million. In addition, the Company also announced the termination of its at-the-market (ATM) sales agreement previously entered into with Cantor Fitzgerald & Co. and its existing equity facility with Aspire Capital, LLC. A copy of the press release is being furnished as Exhibit 99.1 to this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished herewith:
| 99.1 | Press Release dated May 28, 2019. |
ONCOSEC MEDICAL Inc Exhibit
EX-99.1 2 ex99-1.htm OncoSec Medical Incorporated Announces Closing of $11.0 Million Public Offering and Terminates ATM and Other Financing Facility Company Now Has Cash In Excess of $30 Million,…
To view the full exhibit click here
About ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS)
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
